<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086723</url>
  </required_header>
  <id_info>
    <org_study_id>NCI 00B9</org_study_id>
    <secondary_id>NU-NCI-00B9</secondary_id>
    <nct_id>NCT00086723</nct_id>
  </id_info>
  <brief_title>In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer</brief_title>
  <official_title>Phase I/II Trial of In Vivo Angiostatin Generation With Tissue Plasminogen Activator (tPA) and Captopril in Patients With Progressive, Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Tissue plasminogen activator and captopril may help the body generate angiostatin.&#xD;
      Angiostatin may stop the growth of cancer by stopping blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of tissue&#xD;
      plasminogen activator and captopril and to see how well they work in treating patients with&#xD;
      progressive metastatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and toxicity of captopril and tissue plasminogen&#xD;
           activator (tPA) in patients with progressive metastatic cancer.&#xD;
&#xD;
        -  Determine the in vivo generation of angiostatin by western analysis in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the antitumor effect of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive tissue plasminogen activator (tPA) IV over 6 hours and oral captopril twice&#xD;
      daily on days 1-5. Courses repeat every 14 days for up to 1 year in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2&#xD;
      additional courses beyond CR.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of tPA and captopril until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: Not specified.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Angiostatin production</measure>
  </primary_outcome>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant tissue plasminogen activator</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>captopril</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of progressive metastatic cancer, excluding hematologic malignancies (i.e.,&#xD;
             leukemia or lymphoma)&#xD;
&#xD;
          -  Measurable disease not required&#xD;
&#xD;
          -  Must have received at least 1 prior systemic treatment for metastatic disease&#xD;
&#xD;
          -  No known CNS involvement&#xD;
&#xD;
               -  CNS involvement allowed provided it is successfully controlled by prior surgery&#xD;
                  or radiotherapy and there is no current requirement for corticosteroids&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No bleeding diathesis&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT no greater than 3 times upper limit of normal&#xD;
&#xD;
          -  Albumin normal&#xD;
&#xD;
          -  PT and aPTT normal&#xD;
&#xD;
          -  Fibrinogen &gt; lower limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.8 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No history of stroke, transient ischemic attack, or symptoms of cerebral ischemia&#xD;
&#xD;
          -  No history of angioedema with captopril&#xD;
&#xD;
          -  No severe or uncontrolled hypertension (i.e., systolic blood pressure greater than 180&#xD;
             mm Hg or diastolic blood pressure greater than 110 mm Hg)&#xD;
&#xD;
          -  No congestive heart failure requiring therapy&#xD;
&#xD;
          -  No chronic hypotension (e.g., systolic blood pressure less than 100 mm Hg)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Potassium no greater than 5.2 mmol/L&#xD;
&#xD;
          -  No active internal bleeding&#xD;
&#xD;
          -  No history of seizures&#xD;
&#xD;
          -  No psychiatric disorder that would preclude the giving of informed consent or study&#xD;
             follow-up&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No uncontrolled or active bacterial, viral, or invasive fungal infection&#xD;
&#xD;
          -  No recent trauma&#xD;
&#xD;
          -  No medical indication for anticoagulation&#xD;
&#xD;
          -  No contraindication to captopril&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  No concurrent immunomodulator therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior endocrine therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No recent intracranial or intraspinal surgery&#xD;
&#xD;
          -  No concurrent surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 48 hours since prior anticoagulation agents (e.g., warfarin or heparin)&#xD;
&#xD;
          -  More than 3 weeks since prior investigational agents&#xD;
&#xD;
          -  No concurrent anticoagulation agents, aspirin, or nonsteroidal anti-inflammatory drugs&#xD;
&#xD;
          -  No other concurrent investigational agent&#xD;
&#xD;
          -  No concurrent phenytoin, phenobarbital, or other antiepileptic prophylaxis&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed for metastatic bone disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William J. Gradishar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <disposition_first_submitted>February 18, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 18, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 25, 2011</disposition_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Captopril</mesh_term>
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

